chronic kidney disease - International Pharmaceutical Industry

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

News

Positive results for GSK’s anaemia drug daprodustat

GlaxoSmithKline (GSK) has revealed positive data for its investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) daprodustat in patients...

9 November 2021 News anaemia | chronic kidney disease

Continue Reading →

News

New data at ESC Congress 2021 showcase AstraZeneca’s leading cardiovascular, renal and metabolic portfolio

At this year's European Society of Cardiology (ESC) Congress (27-30 August), AstraZeneca is sharing ...

25 August 2021 News AstraZeneca | Brilinta

Continue Reading →

News

US rejects AZ and FibroGen’s anaemia drug roxadustat

The US Food and Drug Administration (US) has handed AstraZeneca a complete response letter (CRL) regarding its anaemia drug roxadustat. AZ had submitted a new dru...

13 August 2021 News anaemia drug | AstraZeneca

Continue Reading →

News

AZ’s Forxiga gains EC, MHRA approvals for chronic kidney disease

AstraZeneca’s Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved by the European Commission for the treatment of chronic ...